Tumour immune rejection triggered by activation of α2-adrenergic receptors
Top Cited Papers
- 7 June 2023
- journal article
- research article
- Published by Springer Nature in Nature
- Vol. 618 (7965) , 607-615
Abstract
Immunotherapy based on immunecheckpoint blockade (ICB) using antibodies induces rejection of tumours and brings clinical benefit in patients with various cancer types1. However, tumours often resist immune rejection. Ongoing efforts trying to increase tumour response rates are based on combinations of ICB with compounds that aim to reduce immunosuppression in the tumour microenvironment but usually have little effect when used as monotherapies2,3. Here we show that agonists of α2-adrenergic receptors (α2-AR) have very strong anti-tumour activity when used as monotherapies in multiple immunocompetent tumour models, including ICB-resistant models, but not in immunodeficient models. We also observed marked effects in human tumour xenografts implanted in mice reconstituted with human lymphocytes. The anti-tumour effects of α2-AR agonists were reverted by α2-AR antagonists, and were absent in Adra2a-knockout (encoding α2a-AR) mice, demonstrating on-target action exerted on host cells, not tumour cells. Tumours from treated mice contained increased infiltrating T lymphocytes and reduced myeloid suppressor cells, which were more apoptotic. Single-cell RNA-sequencing analysis revealed upregulation of innate and adaptive immune response pathways in macrophages and T cells. To exert their anti-tumour effects, α2-AR agonists required CD4+ T lymphocytes, CD8+ T lymphocytes and macrophages. Reconstitution studies in Adra2a-knockout mice indicated that the agonists acted directly on macrophages, increasing their ability to stimulate T lymphocytes. Our results indicate that α2-AR agonists, some of which are available clinically, could substantially improve the clinical efficacy of cancer immunotherapy.Keywords
This publication has 73 references indexed in Scilit:
- Norepinephrine differentially modulates the innate inflammatory response provoked by amyloid-β peptide via action at β-adrenoceptors and activation of cAMP/PKA pathway in human THP-1 macrophagesExperimental Neurology, 2012
- β-Adrenergic Receptor Stimulation and Activation of Protein Kinase A Protect Against α1-Adrenergic–Mediated Phosphorylation of Protein Kinase D and Histone Deacetylase 5Journal of Cardiac Failure, 2011
- Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumorsInflammatory Bowel Diseases, 2009
- Sympathetic nervous system control of anti-influenza CD8+T cell responsesProceedings of the National Academy of Sciences, 2009
- Tec kinases regulate T‐lymphocyte development and function: new insights into the roles of Itk and Rlk/TxkImmunological Reviews, 2009
- Targeting Oncogenes to Improve Breast Cancer ChemotherapyCancer Research, 2006
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- Stimulation of α2-adrenergic receptor inhibits cholangiocarcinoma growth through modulation of Raf-1 and B-Raf activitiesHepatology, 2002
- Toll-like receptors and innate immunityNature Reviews Immunology, 2001
- Central Hypotensive Effects of the α 2a -Adrenergic Receptor SubtypeScience, 1996